Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

Free CME Accredited Learning

Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.

touchONCOLOGY

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
38
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

Reducing attrition and maximizing ADC impact in metastatic breast cancer

Prof. Fatima Cardoso, Asst. Prof. Domen Ribnikar

Watch breast cancer oncologists discuss reducing attrition and maximizing ADC impact in metastatic breast cancer

Translations available:
35 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCASES

Optimizing outcomes in advanced endometrial carcinoma: Navigating guidelines, biomarker-driven immunotherapy, and irAE management

Prof. Nicoletta Colombo, Dr. Ilaria Colombo

Faculty discusses cases of advanced endometrial cancer, reviewing molecular testing, treatment, and toxicity

Translations available:
31 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchTALKS

Unlocking new potential: Rationale and evidence for dual EZH2/AR inhibition in mCRPC

Dr Teresa Alonso Gordoa

Rationale and evidence for dual EZH2/AR inhibition in mCRPC: Dr Teresa Alonso Gordoa shares expert insights on therapy advances

Translations available:
37 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

Computational pathology in NSCLC: From biomarker discovery to clinical integration

Prof. Marina Garassino, Prof. Jakob Nikolas Kather, Prof. Fernando Lopez-Rios

Three experts discuss how computational pathology can enhance diagnosis and treatment in NSCLC.

Translations available:
44 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Shaping the future of PDAC care: Scientific advances and therapeutic innovation

Dr Eileen O'Reilly, Prof. Michel Ducreux, Dr Thomas Hope

Expert faculty discuss how therapeutic innovations will shape the future of care for patients with PDAC

Translations available:
38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Advancing outcomes in CP–CML: Guideline-directed approaches to treatment decision-making, monitoring and toxicity management

Dr Jorge Cortes, Dr Elias Jabbour, Dr Vivian Oehler

The panel reviews treatment decision-making and monitoring for patients with chronic-phase chronic myeloid leukaemia on tyrosine kinase inhibitors.

37 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Targeting brain metastases in advanced NSCLC: The emerging impact of ADCs

Dr Lyudmila Bazhenova, Dr Elvire Pons-Tostivint, Dr Julia Rotow

Expert faculty discuss antibody–drug conjugates (ADCs) in NSCLC with brain metastases, reviewing the clinical trial evidence, practical patient selection and sequencing alongside local CNS therapies, and the emerging pipeline of investigational ADCs.

Translations available:
44 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Evolving paradigms in PNH management: Interpreting the latest data

Prof. Bruno Fattizzo, Dr Austin Kulasekararaj, Dr Srikanth Nagalla

Three experts discuss the latest advances in PNH pathophysiology, diagnosis and therapeutics.

Translations available:
60 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Unlocking the possibilities of BCMA-directed therapies in RRMM: Latest perspectives from IMS and ASH 2025

Dr Rakesh Popat, Dr Paula Rodríguez-Otero, Dr Roberto Mina

Three experts discuss latest data from IMS and ASH 2025 on BCMA-directed agents for multiple myeloma.

Translations available:
93 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCLINICAL PERSPECTIVES

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

Prof. Pasi Jänne, Prof. Nicholas Girard, Dr Helena Yu, Prof. Paul Hofman

This three-part series covers managing advanced NSCLC after EGFR-TKI therapy, highlighting new treatments, biomarkers and MDT-based care.  

Translations available:
42 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

Evolving strategies in low-grade serous ovarian cancer: Applying the evidence to optimize patient care

Dr Kathleen Moore

Expert insights on the pathophysiology and evidence-based treatment of low-grade serous ovarian cancer.

Translations available:
30 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchTALKS

Breakthroughs in treating NSCLC: Targeting KRAS

Dr Christine Bestvina

Targeting KRAS-mutated NSCLC: Dr Christine Bestvina shares expert insights on therapy advances

Translations available:
43 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers

Prof. Thomas Seufferlein, Dr Elizabeth Smyth, Prof.Eric Van Cutsem, Prof. Florian Lordick

Four experts discuss HER2 as a targetable biomarker in BTC and GEA

Translations available:
48 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Delivering state-of-the-art care for GEP-NETs: Evidence-based strategies for PRRT

Prof. Thorvardur Halfdanarson, Prof. Rocio Garcia-Carbonero, Prof. Nicola Fazio

Expert faculty discuss the management of GEP-NETs, with a focus on PRRT

Translations available:
31 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

Staying ahead of the curve in HNSCC care: Refining the role of immunotherapy across disease stages

Prof. Jean-Pascal Machiels

Watch for expert insight on the use of immunotherapy in both recurrent/metastatic and locally advanced HNSCC.

Translations available:
34 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCASES

Applying patient and disease characteristics to guide R/M NPC treatment

Dr Nabil Saba, Dr Victoria Villaflor

Watch two experts discuss how patient and disease characteristics may inform treatment selection in R/M NPC.

Translations available:
Series of 3
CE/CME accredited
touchCurriculum

Management of RRMM with BCMA-directed therapies

Discover the rationale, selection criteria, practical considerations and emerging strategies for optimzing patient outcomes with BCMA-directed therapes in RRMM.
36 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

Therapeutic advances in RRMM: What is the latest on practical application of BCMA-directed therapies?

Prof. Jesús San Miguel, Prof. Pieter Sonneveld, Dr Francesca Gay

Three experts discuss the practicalities of BCMA-directed therapies in RRMM.

Translations available:
Load More...

Society & Congress Partners

touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events

View All

All touchIME CME activities are accredited. Learners can claim ACCME, ANCC, ACPE or EBAC credits upon completion of the activities. This content is for healthcare professionals only.

Latest Medical Education - straight to your inbox

Close Popup